Findings showed 99.9% of participants in the lenacapavir group did not acquire HIV infection. Twice-yearly lenacapavir was found to be superior to daily emtricitabine 200mg and tenofovir disoproxil ...

The US Preventive Services Task Force recently issued a recommendation statement for preexposure prophylaxis (PrEP) for HIV, but it is so broadly worded that it will be subject to vast payer ...

Sara Moniuszko is a health and lifestyle reporter at CBSNews.com. Previously, she wrote for USA Today, where she was selected to help launch the newspaper's wellness vertical. She now covers breaking ...

ATLANTA, Ga. — Georgia pharmacists will be allowed to prescribe HIV prevention medications starting July 1 under a new state ...

A new study found that adults in custody of the Federal Bureau of Prisons have seen improved pre-exposure prophylaxis (PrEP) initiation and sustained treatment uptake for HIV. Rates of HIV ...

The HIV epidemic remains a critical public health priority in the United States. The Ending the HIV Epidemic (EHE) initiative seeks to reduce HIV diagnoses by 75% by 2025 and by 90% by 2030. Certain ...

See more of our trusted coverage when you search. Prefer Newsweek on Google to see more of our trusted coverage when you search. A brand new drug might be more effective at preventing HIV than current ...

See more of our trusted coverage when you search. Prefer Newsweek on Google to see more of our trusted coverage when you search. A new pre-exposure prophylaxis (PrEP) drug has shown promise as a ...

Credit: Gilead. Yeztugo (lenacapavir) is an HIV-1 capsid inhibitor that is administered every 6 months after an initial dosing regimen. Yeztugo demonstrated superiority over Truvada in reducing the ...

An annual injection designed to guard against Human Immunodeficiency Virus (HIV) has completed an important early safety ...